SITE006-0155

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2022-09-01

AEs

Serious

Dropout signal

–

Adverse events

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-09-18 (study day 4); relationship: N

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-21 (study day 7); relationship: not assessed

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-09 (study day 56); relationship: not assessed

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-16 (study day 367); relationship: not assessed

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-10-19 (study day 400); relationship: N

severe serious assessed

Grade 4 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-11-14 (study day 426); relationship: N; serious criteria: life-threatening

Data queries

No data queries.